Gerhard Rogler - Selected Publications#

Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis.
Carone M, Spalinger MR, Gaultney RA, Mezzenga R, Hlavačková K, Mookhoek A, Krebs P, Rogler G, Luciani P, Aleandri S.
Nat Commun. 2023 Jun 13;14(1):3489. doi: 10.1038/s41467-023-39013-3.

A new formulation for rectal (topical) therapies for patients with left sided colitis. A patent has been filed and pharmaceutical development is under way.

Co-cultivation is a powerful approach to produce a robust functionally designed synthetic consortium as a live biotherapeutic product (LBP). Kurt F, Leventhal GE, Spalinger MR, Anthamatten L, Rogalla von Bieberstein P, Menzi C, Reichlin M, Meola M, Rosenthal F, Rogler G, Lacroix C, de Wouters T. Gut Microbes. 2023 Jan-Dec;15(1):2177486. doi: 10.1080/19490976.2023.2177486.

A new co-cultivation method for bacterial consortia is described. A patent has been approved based on the described technology. Gerhard Rogler is co-founder of a start-up called "PharmaBiome" which uses this technology to develop new therapies for ulcerative colitis and other diseases involving the intestinal microbiota. The start-up has won several awards and just signed a development contract with a major pharmaceutical company. See also: https://www.pharmabiome.com/

NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M. J Clin Invest. 2023 Feb 15;133(4):e169304. doi: 10.1172/JCI169304.

A novel connection between two risk genes for IBD

Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Rogler G, Singh A, Kavanaugh A, Rubin DT. Gastroenterology. 2021 Oct;161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042. Epub 2021 Aug 3.

Invited review for the highest ranked GI journal.

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3.

One of many major IBD therapy trials.

Microbial network disturbances in relapsing refractory Crohn's disease. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; Swiss IBD Cohort Investigators; Wiest R, Stelling J, Macpherson AJ. Nat Med. 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z. Epub 2019 Jan 21.

A relevant manuscript on IBD microbiota using samples from the Swiss IBD cohort study for which Gerhard Rogler was the PI for 15 years.

Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner.

Spalinger MR, Schmidt TS, Schwarzfischer M, Hering L, Atrott K, Lang S, Gottier C, Geirnaert A, Lacroix C, Dai X, Rawlings DJ, Chan AC, von Mering C, Rogler G, Scharl M. J Clin Invest. 2019 May 20;129(6):2527-2541. doi: 10.1172/JCI123263. eCollection 2019 May 20.

A study connecting microbiota with PTPN22 , an IBD risk gene

Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation.

Cosin-Roger J, Simmen S, Melhem H, Atrott K, Frey-Wagner I, Hausmann M, de Vallière C, Spalinger MR, Spielmann P, Wenger RH, Zeitz J, Vavricka SR, Rogler G, Ruiz PA. Nat Commun. 2017 Jul 24;8(1):98. doi: 10.1038/s41467-017-00213-3.

Providing pathopyhsiological evidence why IBD patients suffer from flares under conditions of hypoxia such as long distance flights and high altitude

Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, Scharl M, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G. Gut. 2017 Jul;66(7):1216-1224. doi: 10.1136/gutjnl-2015-310297. Epub 2016 Feb 4.

This manuscript contributed to a ban of TiO2 as a food additive by EFSA.

H-index of Gerhard Rogler (Google Scholar, 16.11.2023): 100
h-index since 2018: 68
Citations: 43884
Citations since 2018: 22603
i-10 index: 464